IRINI ELEFTHERIOU (Greece)
National and Kapodistrian University of Athens Second Department of PediatricsAuthor Of 1 Presentation
CHARACTERISTICS OF CHILDREN HOSPITALIZED WITH MIS-C DURING THREE PANDEMIC WAVES IN GREECE
Abstract
Backgrounds:
The Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially severe complication of COVID-19.
Methods
This is a retrospective observational study of children aged <18 years hospitalized with MIS-C in 10 tertiary hospitals in Greece during three pandemic waves characterized by different SARS-CoV-2 variant: i. from August 2020 to January 2021 (EU1-B.1.177), ii. from February 2021 to July 2021 (Alpha-B.1.1.7) and iii. from August 2021 to December 2021 (Delta-B.1.617.2). The aim of the study was to document the incidence over time, clinical characteristics and outcome of children admitted with MIS-C in Greek hospitals during the COVID-19 pandemic.
Results:
In total, 119 patients were included, 91.6% (109/119) met the WHO criteria of MIS-C diagnosis: 26.9% (32/119), 39.5% (47/119) and 33.6% (40/119) were hospitalized during the 1st, 2nd, and 3rd study period, respectively. Demographic and clinical characteristics are shown in Table 1. No cases were found before October 2020. The incidence of MIS-C significantly decreased over the three waves from 3.3/1000 to 0.25/1000 confirmed COVID-19 cases (P <0.0001). No other significant difference was observed in the clinical manifestations and disease severity of children hospitalized with MIS-C over the three waves.
Conclusions/Learning Points:
This study indicates that the incidence of MIS-C may vary according to the predominant variant. Outcome remains favourable regardless of the variant leading to MIS-C. Larger studies are needed to clarify if clinical characteristics and/or disease severity may differ, as well.
Presenter of 1 Presentation
CHARACTERISTICS OF CHILDREN HOSPITALIZED WITH MIS-C DURING THREE PANDEMIC WAVES IN GREECE
Abstract
Backgrounds:
The Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially severe complication of COVID-19.
Methods
This is a retrospective observational study of children aged <18 years hospitalized with MIS-C in 10 tertiary hospitals in Greece during three pandemic waves characterized by different SARS-CoV-2 variant: i. from August 2020 to January 2021 (EU1-B.1.177), ii. from February 2021 to July 2021 (Alpha-B.1.1.7) and iii. from August 2021 to December 2021 (Delta-B.1.617.2). The aim of the study was to document the incidence over time, clinical characteristics and outcome of children admitted with MIS-C in Greek hospitals during the COVID-19 pandemic.
Results:
In total, 119 patients were included, 91.6% (109/119) met the WHO criteria of MIS-C diagnosis: 26.9% (32/119), 39.5% (47/119) and 33.6% (40/119) were hospitalized during the 1st, 2nd, and 3rd study period, respectively. Demographic and clinical characteristics are shown in Table 1. No cases were found before October 2020. The incidence of MIS-C significantly decreased over the three waves from 3.3/1000 to 0.25/1000 confirmed COVID-19 cases (P <0.0001). No other significant difference was observed in the clinical manifestations and disease severity of children hospitalized with MIS-C over the three waves.
Conclusions/Learning Points:
This study indicates that the incidence of MIS-C may vary according to the predominant variant. Outcome remains favourable regardless of the variant leading to MIS-C. Larger studies are needed to clarify if clinical characteristics and/or disease severity may differ, as well.
Moderator of 1 Session
Poster Author Of 9 e-Posters
EP421 - RISK FACTORS FOR SEVERE COVID-19 DISEASE IN CHILDREN (ID 1019)
EP425 - THE EFFECT OF DIFFERENT SARS-COV-2 VARIANTS ON CHILDREN’S HOSPITALIZATIONS AND COVID-19 SEVERITY (ID 955)
EP426 - BRONCHIOLITIS AND COVID-19 IN INFANTS AND YOUNG CHILDREN: AN UNUSUAL PAIR (ID 967)
PD053 - COVID-19 BREAKTHROUGH DISEASE IN FULLY VACCINATED PAEDIATRIC PATIENTS WITH RHEUMATIC DISEASES (ID 1002)
PD083 - IMPACT OF COVID-19 ON ANTIMICROBIAL CONSUMPTION IN HOSPITALIZED CHILDREN (ID 812)
PD090 - ANTIMICROBIAL PRESCRIBING IN HOSPITALIZED CHILDREN WITH COVID-19 (ID 816)
PD122 - MANAGEMENT OF INFANTS 29-60 DAYS OLD HOSPITALIZED WITH FEVER: TIME TO REVISIT PRACTICE GUIDELINES? (ID 1880)
PD161 - SEROPREVALENCE OF SARS-COV-2 INFECTION AMONG CHILDREN AND THEIR PARENTS IN GREECE (ID 786)
- Dimitra Dimopoulou (Greece)
- Maria Kyritsi (Greece)
- Eleni Vergadi (Greece)
- Ekaterini Tsiligianni (Greece)
- Eleni Papadimitriou (Greece)
- Artemis Mavridi (Greece)
- Spyridon Giannakopoulos (Greece)
- Georgia Tsiourvopoulou (Greece)
- Maria Palyvou (Greece)
- Evangelia Angeli (Greece)
- Nikitas Brikos (Greece)
- IRINI ELEFTHERIOU (Greece)
- Nikos SPYRIDIS (Greece)
- Athanasios Michos (Greece)
- Vassiliki Spoulou (Greece)
- Despoina Gkentzi (Greece)
- Ekaterini Siomou (Greece)
- Vassiliki Papaevangelou (Greece)
- George A. Syrogiannopoulos (Greece)
- Emmanouil Galanakis (Greece)
- Christos Hadjichristodoulou (Greece)
- Maria Tsolia (Greece)
PD168 - MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C): A NATIONWIDE COLLABORATIVE STUDY IN THE GREEK POPULATION (ID 774)
- STAVROULA LAMPIDI (Greece)
- Despoina Maritsi (Greece)
- IRINI ELEFTHERIOU (Greece)
- Evaggelia Farmaki (Greece)
- Nikos SPYRIDIS (Greece)
- KONSTANTINA CHARISI (Greece)
- Petrina Vantsi (Greece)
- Filippos G. Filippatos (Greece)
- Kleopatra Skourti (Greece)
- EFIMIA PAPADOPOULOU-ALATAKI (Greece)
- Kyriaki Papadopoulou-Legbelou (Greece)
- Parthena Kampouridou (Greece)
- Ioanna N. Grivea (Greece)
- Eleni Vergadi (Greece)
- Despoina Gkentzi (Greece)
- Despina Dimou (Greece)
- Patra Koletsi (Greece)
- Lampros Fotis (Greece)
- Vassiliki Papaevangelou (Greece)
- Gabriel Dimitriou (Greece)
- Emmanouil Galanakis (Greece)
- George A. Syrogiannopoulos (Greece)
- Vassiliki Spoulou (Greece)
- Athanasios Michos (Greece)
- Emmanuel Roilides (Greece)
- Maria Tsolia (Greece)